Fruquintinib is currently in clinical development for the treatment of refractory metastatic colorectal cancer (mCRC). Colorectal (or bowel) cancer starts in the large bowel (colon) and the back passage (rectum). The cause of colorectal cancer is unknown but various factors increase the risk of having it, including having a diet high in red or processed meats and low in fibre, smoking, and being overweight or obese. Metastatic cancer is cancer that has spread around the body from the place it had originally started from. Patients with mCRC have limited treatment options following progression on standard therapies, and treatment options include reuse of prior therapies. Therefore, there is an unmet medical need for additional safe and effective treatment.
Fruquintinib for treating refractory metastatic colorectal cancer
Fruquintinib is currently in clinical development for the treatment of refractory metastatic colorectal cancer (mCRC). Colorectal (or bowel) cancer starts in the large bowel (colon) and the back passage (rectum). The cause of colorectal cancer is unknown but various factors increase the risk of having it, including having a diet high in red or processed meats and low in fibre, smoking, and being overweight or obese.